

EXTRA-ARTICULAR MANIFESTATIONS IN RHEUMATOID ARTHRITIS - PREDICTORS OF NONVERTEBRAL FRACTURES

Mihailov Claudia^{1,2}, Mitroi Adrian^{1,2}

¹ Faculty of Medicine, "Ovidius" University of Constanta, Romania

² Clinical Railway Hospital Constanta, Romania

Adrian Mitroi

email: mitroi_74@yahoo.com

phone: +40 241583355

ABSTRACT

Introduction: In rheumatoid arthritis the extra-articular manifestations present a marker of disease severity and are accompanied by increased morbidity and mortality.

Objectives: The aim of this paper is to study the relationship between extra-articular manifestations and nonvertebral fractures in patients with rheumatoid arthritis.

Methods: The study included 130 menopausal women diagnosed with rheumatoid arthritis. Bone mineral density was measured at lumbar spine and femoral by means of dual X-ray osteodensitometry. Nonvertebral fractures such as femur, humerus, or forearm fractures were diagnosed through questioning the subjects. The obtained variables were analyzed by bivariate analysis and logistic regression.

Results: The mean age was 62.77 ± 7.51 years old. The medium duration of rheumatoid arthritis was 7.91 ± 7.85 years, the frequency of extra-articular manifestations was 25.38%. The frequency of nonvertebral fractures was 19.23%. The frequency of nonvertebral fractures is statistically significantly higher in patients with rheumatoid arthritis who have extra-articular manifestations (36.36% vs 13.40%, $p = 0.008$).

Conclusions: In the presence of extra-articular manifestations in patients with rheumatoid arthritis, primary prevention measures are required for nonvertebral fractures.

Keywords: rheumatoid arthritis, nonvertebral fractures, extra-articular manifestations

Introduction

Rheumatoid arthritis (RA) is a disease characterized by chronic systemic inflammation that especially affects the joints through cytokines, chemokines and metalloproteinases. Approximately 40% of patients with RA present extra-articular manifestations (EAMs) (1,2) such as pleuropulmonary, cutaneous, cardiovascular, hematological bone (ex: osteoporosis) manifestations. They are found especially in patients with severe forms of the disease, with the presence of high titres anti-cyclic citrullinated protein antibodies (anti-CCP) and rheumatoid factor (FR). EAMs occur mainly

due to the systemic inflammatory process, being pathogenically mediated by the action of the same cytokines that determine the articular manifestations. (3, 4) EAMs present a marker of disease severity and are accompanied by increased morbidity and mortality. (5)

Methods

One hundred and thirty women, consecutively admitted in the Rheumatology Clinical, were included in the study. They are menopausal and are between 49 and 82 years old. All the patients fulfilled ACR 1987 revised for RA criteria (6).

The patients are living in the Constanta district and have a disease duration of at least 2 years (patients with early RA were excluded).

Demographic variables, variables related to RA and therapeutic variables were obtained by interview (Table 1). The following parameters were collected: age, body mass index, living environment (rural or urban), duration of menopause, smoker or not, bone mineral density, osteoporotic fractures, stage of RA, age of RA onset, duration of RA, the presence of EAMs (represented by anaemia of chronic disease, pulmonary fibrosis and rheumatoid nodules), presence of RF, erythrocyte sedimentation rate (ESR) level, C reactive protein (CRP) level, the score of disease activity measured by DAS 28 (Disease Activity Score 28), physical disability quantified by MHAQ score (modified Health Assessment Questionnaire), treatment of RA (disease modifying antirheumatic drugs, DMARD), corticoid treatment.

Global assessment of disease activity was realized by measuring it on a visual analogue scale – VAS from 0 to 100 mm. Joint evaluation consisted in counting the painful joints (28 joints) and swollen joints (28 joints). Disease activity score (DAS 28) was calculated using the 28 joints, VAS and ESR (7).

Physical disability was assessed by the modified Health Assessment Questionnaire, (M-HAQ) (8).

Bone mineral density was measured at lumbar level (L2-L4) and femur level (femoral neck, entire femoral bone) by Dual Energy X-Ray Absorptiometry (DXA) by means of a DPX-Aplha (Lunar – General Electric) machine.

Bone mass was assessed by means of BMD (mg/cm²), T score and Z score. Osteoporosis was defined, based on WHO proposal, when T score was with at least 2.5 SD under the medium of a young adult, a value of ± 1 SD was considered normal while a value between -1 and -2.5 was considered osteopenia (9).

Diagnosis of vertebral fracture (T4-L5) was made by means of dorso-lumbar spine X-ray – which was performed in each patient by the same experienced radiologist. A semi-quantitative method was used (type Genant) (10).

Table 1. General features of study group (n=130)

DEMOGRAPHIC VARIABLES	
Age (years)	62.77 $\pm$ 7.51
Urban environment,(%)	102(78.46)
Rural environment, (%)	28(21.54)
BMI (kg/m ²)	27.62 $\pm$ 4.43
Duration of menopause (years)	16.42 $\pm$ 8.15
Smoker (%)	23(17.69%)
Former smoker (%)	18(13.85%)
BONE MINERAL DENSITY	
Osteoporosis (%)	58(44.62%)
Osteopenia (%)	39(30%)
BMD normal (%)	33(25.38%)
FRACTURES	
Vertebral fractures	22 (16.92%)
Nonvertebral fractures	25 (19.23%)
RHEUMATOID ARTHRITIS VARIABLES	
RA stage	
II, (%)	63(48.46%)
III, (%)	40(30.77%)
IV, (%)	27(20.77%)
Rheumatoid factor, (%)	97(74.62%)
Extra-articular manifestations (%)	33(25.38%)
Age of RA onset (years)	54.86 $\pm$ 9.89
Duration of RA (years)	7.91 $\pm$ 7.85
MHAQ	1.61 $\pm$ 0.50
DAS 28	4.77 $\pm$ 1.2
ESR (mm/h)	48.62 $\pm$ 29.45
CRP (mg/dL)	8.62 $\pm$ 18.49
THERAPY VARIABLES	
Glucocorticoids	
Current user, (%)	49(37.69)
Ever user, (%)	76(58.46)
Disease modifying Antirheumatic Drugs	
Methotrexate, (%)	58(44.62)
Salazopirine, (%)	18(13.85)
Leflunomide, (%)	63(48.46)
Hydroxychloroquine, (%)	21(16.15)
Combinations of DMARD, (%)	27(20.77)
Biological, (%)	12(9.23)
BMI – body mass index; RA – rheumatoid arthritis; MHAQ – modified Health Assessment Questionnaire; DAS 28 – disease activity score; ESR – erythrocytes sedimentation rate; PCR – C reactive protein; DMARD - disease modifying antirheumatic drugs	

Nonvertebral fractures (NVFs) such as femur, humerus, or forearm fractures were diagnosed through questioning the subjects. Fractures which occurred as a result of minor trauma such as falling from standing height were considered to be osteoporotic fractures.

Bivariate analysis was used to compare demographic variables as well as variables related to RA in patients with and without

EAMs. For continuous variables with normal distribution comparison “t student” test was used while for the ones with non-normal distribution Mann-Whitney U test was used. For dichotomous variables was used χ^2 test. P value was considered statistically significant when less than 0.05. Logistic regression was used to verify if EAMs can be considered independent risk factors for NVFs.

Statistical analysis was performed using a computer program MedCalc for Windows, 10th version).

Results

The characteristics of the studied group are presented in Table 1. EAMs were present in 33 patients: 27 patients had anaemia of chronic disease, 10 patients rheumatoid nodules, and 3 patients pulmonary fibrosis.

We compared patients with RA who have EAMs with those who do not have EAMs. Table no. 2 presents the bivariate analysis of patients with RA depending on the presence of EAMs.

The demographic variables by which patients with EAMs differ statistically significantly from those without EAMs are: older age, the environment of origin, longer menopause and former smoker status.

The frequency of osteoporosis is statistically significantly higher in patients with RA who have EAMs compared to those without EAMs (81.82% vs 31.96%). The frequency of osteopenia and normal BMD is statistically significantly higher among patients who do not have EAMs.

Patients with EAMs differ statistically significantly from those without EAMs and in terms of NVFs (36.36% vs 13.40%, p : 0.008).

The variables dependent on RA in which patients with EAMs differ statistically significantly from those without EAMs are represented by: higher MHAQ, higher DAS 28, higher ESR and higher PCR. In stage II of RA, the percentage of patients with EAMs is statistically significantly lower than those who do not have EAMs (27.27% vs 55.67%)

The current use of corticosteroids (CS) is statistically significantly higher in the group of patients with EAMs compared to those without

EAMs (54.55% vs 31.96%). Methotrexate, sulfasalazine and combinations of DMARDs are the background drugs by which patients with EMAs differ statistically significantly from those without EAMs.

We used logistic regression and found that EAMs are a risk factor for nonvertebral fractures. (Table 2).

Table 2 Logistic regression

Variable	Coefficient	SD	P	Odds ratio	95% CI
EAMs	1.09	0.49	0.025	2.98	1.14 – 7.81
Osteoporosis	0.97	0.49	0.04	2.65	1.00 – 7.02

SD: standard deviation; CI: confidence interval; EAMs: Extra-articular manifestations;
Logistic regression shows that EAMs and osteoporosis may be risk factors for nonvertebral fractures.

Discussions

In our study the risk factors for NVFs in menopausal RA patients are represented by: age, duration of menopause and osteoporosis; background treatment used in rheumatoid arthritis and corticosteroids have not been identified as risk factors for NVFs.

The presence of EAMs is statistically significantly associated with nonvertebral fractures (NVF), but on the other hand patients with EAMs are older, longer menopause and the frequency of osteoporosis is higher - variables that represent risk factors for NVFs (Table 3).

Using logistic regression, we found that EAMs are a risk factor for NVFs. Thus, the risk of a patient with EAMs to suffer a NVFS, after adjusting for osteoporosis, is 2.65 times higher compared to a patient without EAMs (Table 2).

Table 3. Comparison between patients with and without extra-articular manifestations

	without EMAs n=108	with EMAs n=22	P
VARIABLE DEMOGRAFICE			
Age (years)	61.42±6.94	66.73±7.83	0.0004
Urban environment, (%)	69(71.13)	33(100)	0.001
Rural environment, (%)	28(28.87)	0(0)	0.001
BMI (kg/m2)	27.64±4.04	28.06±5.30	0.630
Duration of menopause (years)	14.71±7.34	21.45±8.46	<0.0001
Smoker (%)	14(14.43)	9(27.27)	0.159
Former smoker (%)	18(15.86)	0(0)	0.017
BONE MINERAL DENSITY			
Osteoporosis, (%)	31(31.96)	27(81.82)	<0.0001
Osteopenia, (%)	36(37.11)	3(9.09)	0.004
BMD normal, (%)	30(30.93)	3(9.09)	0.023
OSTEOPOROTIC FRACTURES			
Nonvertebral fractures	13(13.40%)	12(36.36%)	0.008
RHEUMATOID ARTHRITIS VARIABLES			
RA stage			
II, (%)	54(55.67)	9(27.27)	0.008
III, (%)	25(25.77)	15(45.45)	0.057
IV, (%)	18(18.56)	9(27.27)	0.413
Rheumatoid factor, (%)	70(72.16)	27(81.82)	0.384
Age of RA onset (years)	54.13±9.52	57.00±10.37	0.146
Duration of RA (years)	7.29±8.08	9.73±6.90	0.123
MHAQ	1.53±0.48	1.85±0.48	0.003
DAS 28	4.43±1.15	5.79±0.66	<0.0001
ESR (mm/h)	37.54±21.49	81.18±25.39	<0.0001
CRP (mg/dL)	4.23±6.19	21.51±32.16	<0.0001
THERAPY VARIABLES			
Glucocorticoids			
Current user, (%)	31(31.96)	18(54.55)	0.035
Ever user, (%)	55(56.70)	21(63.64)	0.621
DMARDs			
Methotrexate, (%)	34(34.05)	27(72.73)	0.0004
Salazopirine, (%)	9(9.28)	9(27.27)	0.021
Leflunomide, (%)	45(46.39)	18(54.55)	0.543
HQ, (%)	15(15.46)	6(18.18)	0.092
Combinations of DMARD, (%)	9(9.28)	18(54.55)	<0.0001
Biological, (%)	12(12.37)	0(0)	0.076

EAMs - extra-articular manifestations; BMI – body mass index; MHAQ – modified Health Assessment Questionnaire; DAS 28 – disease activity score; ESR – erythrocytes sedimentation rate; PCR – C reactive protein; DMARD - disease modifying antirheumatic drugs; HQ - Hydroxychloroquine

In the literature we found only one study evaluated the risk of patients with extra-articular manifestations suffering a NVF; This is the study of Van Staa (11) who chose from the EAMs only pulmonary fibrosis, and from NVFs only those of the femur, and found that the risk of femoral fracture of a patient with RA who also has pulmonary fibrosis is 4.9 times higher compared to the patients in the control group.

Because EMAs are a risk factor for NVFs independent of osteoporosis and RA-dependent variables have not been identified as a risk factor for NVFs, we consider that the mechanism by which EAMs are involved in NVFs is favored by falls, the EAMs correlating with the severe forms of RA in which the walking ability is also affected.

Conclusions

In the presence of extra-articular manifestations in patients with rheumatoid arthritis, primary prevention measures are required for nonvertebral fractures, the most important of which are the reduction of modifiable risk factors for falls and the prevention / treatment of osteoporosis.

Conflict of interest statement

The authors declare that they have no conflict of interests.

References

1. Cimmino MA, Salvarani C, Macchioni P, Montecucco C, Fossaluzza V, Mascia MT, Punzi L, Davoli C, Filippini D, Numo R. Extra-articular manifestations in 587 Italian patients with rheumatoid arthritis. *Rheumatol Int.* 2000;19(6):213-7.
2. Horton MR. Rheumatoid arthritis associated interstitial lung disease. *Crit Rev Comput*

Tomogr. 2004;45:429–40.

3. Picerno V, Ferro F, Adinolfi A, Valentini E, Tani C, Alunno A. One year in review: the pathogenesis of rheumatoid arthritis. *Clin Exp Rheumatol*. 2015;33:551–8;
4. Turesson C. Extra-articular rheumatoid arthritis. *Curr Opin. Rheumatol*. 2013; 25(3):360–6.
5. Turesson C, Matteson EL. Management of extra-articular disease manifestations in rheumatoid arthritis. *Curr Opin Rheumatol*. 2004;16(3):206–11.
6. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. *Arthritis Rheum* 1988;31:315-24
7. van der Heijde DM, van't HM, van Riel PL, van de Putte LB. Development of a disease activity score based on judgment in clinical practice by rheumatologists. *J Rheumatol* 1993; 20:579-81
8. Picus T, Summey JA, Soraci SA. Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire. *Arthritis Rheum* 1983; 26:1346-53
9. Kanis JA, Melton LJ III, Christiansen C et al. The diagnosis of osteoporosis. *J Bone Miner res* 1994; 9:1137-41
10. Genant HK, Wu CY, van Kuijk et al. Vertebral fracture assessment using a semiquantitative technique. *J Bone Miner res* 1993; 8:1137-48
11. Van Staa T P, Geusens P, Bijlsma J W J. Clinical assessment of the longterm risk of fracture in patients with rheumatoid arthritis. *Arthritis Rheum* 2006 Oct; 54(10):3104-12